美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

SpyGlass Pharma, Inc.

28.00

-0.3500-1.23%

盘后：28.000.00000.00%17:42 EST

成交量：4.47万

成交额：125.93万

市值：8.94亿

市盈率：-25.02

高：28.54

开：28.21

低：27.81

收：28.35

52周最高：32.44

52周最低：20.16

股本：3,191.12万

流通股本：940.00万

量比：0.88

换手率：0.48%

股息：- -

股息率：- -

每股收益(TTM):-1.1190

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值

异动解读 | SpyGlass Pharma纳斯达克IPO首日开盘价翻倍，盘中大涨50%

BUZZ-SpyGlass 在纳斯达克首次公开募股 1.5 亿美元后有望高开

美股异动 | SpyGlass Pharma(SGP.US)登陆美股市场开盘暴涨超43%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/SGP/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SGP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","market":"US","secType":"STK","nameCN":"SpyGlass Pharma, Inc.","latestPrice":28,"timestamp":1772226000000,"preClose":28.35,"halted":0,"volume":44687,"hourTrading":{"tag":"盘后","latestPrice":28,"preClose":28,"latestTime":"17:42 EST","volume":229,"amount":6440.02,"timestamp":1772232135306,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.012345679012345729,"floatShares":9400000,"shares":31911200,"eps":-1.119,"marketStatus":"休市中","change":-0.35,"latestTime":"02-27 16:00:00 EST","open":28.21,"high":28.54,"low":27.81,"amount":1259313.666807,"amplitude":0.02575,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.119,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":28.35,"postHourTrading":{"tag":"盘后","latestPrice":28,"preClose":28,"latestTime":"17:42 EST","volume":229,"amount":6440.02,"timestamp":1772232135306,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8790983987120589},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","floatShares":9400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8790983987120589,"shares":31911200,"dividePrice":0,"high":28.54,"amplitude":0.02575,"preClose":28.35,"low":27.81,"week52Low":20.16,"pbRate":"--","week52High":32.44,"institutionHeld":0,"latestPrice":28,"eps":-1.119,"divideRate":0,"volume":44687,"delay":0,"ttmEps":-1.119,"open":28.21,"prevYearClose":16,"prevWeekClose":29.32,"prevMonthClose":28,"prevQuarterClose":16,"fiveDayClose":29.32,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SGP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SGP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SGP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SGP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613789435","title":"旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2613789435","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613789435?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 19:54","pubTimestamp":1771847674,"startTime":"0","endTime":"0","summary":"更新版 3-旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值在第 3、6、7 段添加分析师评论Arasu Kannagi Basil路透2月23日 - 药物开发商Generate Biomedicines周一表示，该公司在美国首次公开募股的目标估值将高达21.7亿美元，从而进入上市步伐加快的生物技术市场。Aktis Oncology AKTS.O、Agomab Therapeutics AGMB.O、Veradermics MANE.N、Eikon Therapeutics EIKN.O和SpyGlass Pharma SGP.O今年已经登陆美国资本市场。\"Generate公司用于治疗严重哮喘的主要候选产品GB-0895正在进行后期试验。预计这项研究将于 2028 年上半年全部完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ0Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","LU0795875169.SGD","BK4534","IE00B2B36J28.USD","LU1868836914.USD","LU2133065610.SGD","SGP","LU0912757837.SGD","LU2111349929.HKD","AGMB","LU2750360997.AUD","LU1804176565.USD","LU2237443465.HKD","LU0234570918.USD","BK4552","MRNX","AMGN","BK4516","LU2265009873.SGD","BK4566","LU0096364046.USD","BK4139","LU0251142724.SGD","LU0320765992.SGD","IE00BKVL7J92.USD","BK4127","BK4550","MRNY","LU0098860793.USD","LU1868836757.USD","EIKN","LU2750360641.GBP","PIPR","IE00BJJMRZ35.SGD","LU0106261372.USD","MRNA","BK4532","LU2471134796.USD","GSX","LU1162221912.USD","LU1244550494.USD","IE0004091025.USD","LU1791807156.HKD","LU0122379950.USD","LU2237443622.USD","LU0889565916.HKD","LU2089283258.USD","AKTS","IE0009355771.USD","LU2028103732.USD"],"gpt_icon":0},{"id":"1173758808","title":"异动解读 | SpyGlass Pharma纳斯达克IPO首日开盘价翻倍，盘中大涨50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173758808","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173758808?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 01:29","pubTimestamp":1770398971,"startTime":"0","endTime":"0","summary":"生物制药公司SpyGlass Pharma, Inc.今日盘中股价大幅上涨，涨幅达到50.00%，引起了市场的广泛关注。消息面上，SpyGlass Pharma今日在纳斯达克成功完成首次公开募股，开盘价达到每股32美元，远高于其16美元的发行价。此次IPO以每股15至17美元的价格区间出售了约940万股股票，共融资1.5亿美元。SpyGlass Pharma成立于2019年，专注于为慢性眼病开发长效疗法的药物输送系统。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SGP"],"gpt_icon":0},{"id":"2609898590","title":"BUZZ-SpyGlass 在纳斯达克首次公开募股 1.5 亿美元后有望高开","url":"https://stock-news.laohu8.com/highlight/detail?id=2609898590","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609898590?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 00:00","pubTimestamp":1770393659,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4T3Z21PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","BK4585","BK4127","BK4559","LU0648001328.SGD","BK4534","LU1201861249.SGD","IE00BSNM7G36.USD","LU0106831901.USD","LU1162221912.USD","LU2360032135.SGD","LU0310800965.SGD","LU1244550494.USD","LU2236285917.USD","LU1267930227.SGD","BK4207","LU0130102774.USD","LU0162691827.USD","LU1366192091.USD","LU0052756011.USD","LU0098860793.USD","LU1244550221.USD","LU2456880835.USD","LU0980610538.SGD","BK4504","LU0128525689.USD","LU1506573853.SGD","LU0072461881.USD","LU0314106906.USD","LU0320765646.SGD","LU1244550577.SGD","LU2125154935.USD","LU0130517989.USD","LU1668664300.SGD","BK4588","MNSH","BK4566","LU2125154778.USD","LU2417539215.USD","SGP","LU1791807156.HKD","LU0477156953.USD","SF","LU2462157665.USD"],"gpt_icon":0},{"id":"2609839513","title":"美股异动 | SpyGlass Pharma(SGP.US)登陆美股市场 开盘暴涨超43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609839513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609839513?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 00:00","pubTimestamp":1770393633,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，SpyGlass Pharma(SGP.US)登陆美股市场，开盘股价暴涨超43%，报23美元，IPO价格为16美元。SpyGlass Pharma 是一家临床后期生物技术公司，专注于开发 用于慢性眼部疾病的持续药物输送系统，旨在通过更长效、可持续的治疗方案改善患者的视力和生活质量。其核心研发产品包括一种将药物输送垫与人工晶状体结合的系统，用于治疗像 开角型青光眼或眼压高 等慢性眼病。这类治疗目标是提高疗效和患者依从性，与传统每日滴眼药水相比有潜在优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IWO","BK4550","UWM","TWM","IWN","BK4534","BK4588","SGP","BK4585","BK4581","MNQmain","TNA","SRTY","RWM","TZA","BK4535"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}